These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34429340)

  • 1. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.
    Højsgaard Chow H; Talbot J; Lundell H; Gøbel Madsen C; Marstrand L; Lange T; Mahler MR; Buhelt S; Holm Hansen R; Blinkenberg M; Romme Christensen J; Soelberg Sørensen P; Rode von Essen M; Siebner HR; Sellebjerg F
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
    Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    Talbot J; Højsgaard Chow H; Holm Hansen R; von Essen MR; Sellebjerg F
    J Neuroimmunol; 2021 Dec; 361():577756. PubMed ID: 34739914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal CD8
    von Essen MR; Talbot J; Hansen RHH; Chow HH; Lundell H; Siebner HR; Sellebjerg F
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37369602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
    Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
    Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.
    Reyes S; Smets I; Holden D; Carrillo-Loza K; Christmas T; Bianchi L; Ammoscato F; Turner B; Marta M; Schmierer K; Giovannoni G; Gnanapavan S
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32826298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
    Schneider R; Bellenberg B; Gisevius B; Hirschberg S; Sankowski R; Prinz M; Gold R; Lukas C; Haghikia A
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33172960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF chitinase 3-like-1 association with disability of primary progressive MS.
    Pérez-Miralles F; Prefasi D; García-Merino A; Gascón-Giménez F; Medrano N; Castillo-Villalba J; Cubas L; Alcalá C; Gil-Perotín S; Gómez-Ballesteros R; Maurino J; Álvarez-García E; Casanova B
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32611760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.